Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-19-060615)

Filing Details

Accession Number:: 0001209191-19-060615
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-16 15:10:19
Reporting Period:: 2019-12-12

Accepted Time:: 2019-12-16 15:10:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178253	Scynexis Inc	SCYX	Pharmaceutical Preparations (2834)	562181648

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1408870	Marco Taglietti	1 Evertrust Plaza, 13Th Floor Jersey City NJ 07302-6548	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-12-12	166,667	$0.90	693,682	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (right to buy)	Acquisiton	2019-12-12	166,667	$0.00	166,667	$1.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
166,667	2019-12-12		No	4	P	Direct

Footnotes

Reflects the purchase on December 12, 2019, of 166,667 shares of the issuer's common stock at a public offering price of $0.90 per share of common stock and accompanying warrant.
The warrant expires on the earlier of (i) such date that is six months after the issuer publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023.